ArticleBMC endocrine disorders2026
The association between sarcopenia and carotid artery plaque: a mediation analysis of inflammatory biomarkers.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarotid artery plaque (CAP) and sarcopenia are notable complications in patients with type 2 diabetes mellitus (T2DM). This study aims to explore whether the inflammatory biomarkers neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory response index (SIRI) mediate the association between sarcopenia and CAP in such patients.
methodsSarcopenia was diagnosed using the criteria of the Asian Working Group for Sarcopenia (AWGS 2019), and CAP was assessed by carotid ultrasonography. Inflammatory biomarkers including NLR and SIRI were calculated, with their natural logarithm-transformed values (Ln-NLR, Ln-SIRI) derived. Restricted cubic spline (RCS) analysis, univariate and multivariate logistic regression analyses were used to investigate the associations among these inflammatory biomarkers, sarcopenia and CAP. Additionally, mediation analysis was performed to explore the mediating role of these inflammatory biomarkers.
resultsA total of 749 patients with T2DM were enrolled in this study. The prevalence of CAP and sarcopenia in the study was 58.9% (n=441) and 33.9% (n=254), respectively. Patients with CAP had significantly higher levels of NLR, SIRI, and a higher prevalence of sarcopenia than those without CAP (all p < 0.05). RCS analysis revealed linear correlations of NLR and SIRI with both sarcopenia and CAP (all p for nonlinear > 0.05). Multivariate logistic regression analysis showed that sarcopenia (adjusted odds ratio (aOR) = 1.67, 95% confidence interval (CI): 1.10-2.54, p = 0.016), NLR (aOR = 1.63, 95% CI: 1.01-2.66, p = 0.047), SIRI (aOR = 1.23, 95% CI: 1.01-1.59, p = 0.046), Ln-NLR (aOR = 1.77, 95% CI: 1.10-2.80, p = 0.037), and Ln-SIRI (aOR = 1.38, 95% CI: 1.02-1.74, p = 0.035) were independently and positively associated with CAP. Mediation analysis further indicated that NLR and SIRI partially mediated the association between sarcopenia and CAP, with mediated proportions of 10.39% and 11.40%, respectively. Similarly, Ln-NLR and Ln-SIRI also exerted partial mediating effects, with mediated proportions of 9.73% and 9.29%.
conclusionsSarcopenia is an independently positively associated factor for CAP in patients with T2DM. NLR and SIRI may partially account for the association between sarcopenia and CAP. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.